Efficacy and safety of desvenlafaxine succinate in the treatment of major depressive disorder

Future Neurology

Volumn 2, Issue 4, 2007, Pages 361-371

  Kamath, Jayesh ^a   DeMartinis, Nicholas ^a   Handratta, Venkatesh ^a  

^a UNIVERSITY OF CONNECTICUT SCHOOL OF MEDICINE   (United States)

Author keywords

Antidepressant; Desvenlafaxine; Major depressive disorder; Serotonin norepinephrine reuptake inhibitor; Venlafaxine

Indexed keywords

ANTIDEPRESSANT AGENT; CYTOCHROME P450 3A4; DESVENLAFAXINE; DULOXETINE; MILNACIPRAN; MIRTAZAPINE; MONOAMINE OXIDASE INHIBITOR; NEFAZODONE; NORADRENALIN; PLACEBO; SEROTONIN; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT; VENLAFAXINE;

ANOREXIA; ARTICLE; BINDING AFFINITY; CLINICAL GLOBAL IMPRESSION SCALE; CLINICAL TRIAL; COMORBIDITY; CONSTIPATION; DIABETIC NEUROPATHY; DIASTOLIC BLOOD PRESSURE; DIZZINESS; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG EXCRETION; DRUG HALF LIFE; DRUG METABOLISM; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EJACULATION DISORDER; ENZYME INHIBITION; FIBROMYALGIA; GENERALIZED ANXIETY DISORDER; HAMILTON SCALE; HEALTH CARE COST; HEART RATE; HOT FLUSH; HUMAN; HYPERTENSION; IC 50; IMPOTENCE; INSOMNIA; MAJOR DEPRESSION; MAXIMUM PLASMA CONCENTRATION; MIGRAINE; MONTGOMERY ASBERG DEPRESSION RATING SCALE; NAUSEA; ORGASM; PAIN ASSESSMENT; PANIC; PHARMACODYNAMICS; PREVALENCE; PRIORITY JOURNAL; PULSE RATE; QT INTERVAL; RELAPSE; SEX DIFFERENCE; SIDE EFFECT; SOCIAL PHOBIA; SOMNOLENCE; SUSTAINED RELEASE FORMULATION; SWEATING; SYSTOLIC BLOOD PRESSURE; VASOMOTOR DISORDER; VISUAL ANALOG SCALE; WEIGHT REDUCTION; XEROSTOMIA;

EID: 34447332209     PISSN: 14796708     EISSN: None     Source Type: Journal    
DOI: 10.2217/14796708.2.4.361     Document Type: Article

References (57)

1. Weissman MM, Bruce ML, Leaf PJ et al.: Affective disorders. In: Psychiatric Disorders in America: the Epidemiologic Catchment Area Study. Robins LN, Regier DA (Eds). The Free Press, NY, USA, 53-80 (1991).
2. Kessler RC, McGonagle KA, Zhao S et al.: Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Results from the National Comorbidity Survey. Arch. Gen. Psychiatry 51, 8-19 (1994).
3. U.S. Department of Health and Human Services. Public Health Service, Agency for Health Care Policy and Research, Depression Guideline Panel: Clinical practice guidelines, number 5. Depression in Primary Care: Volume 1. Detection and diagnosis. Rockville, MD, USA, AHCPR Publication No. 93-0550 (1993).
4. Evans DL, Charney DS, Lewis L et al.: Mood disorders in the medically ill: scientific review and recommendations. Biol. Psychiatry 58(3), 175-189 (2005).
5. Simon GE, Von Korff M, Barlow W: Health care costs of primary care patients with recognized depression. Arch. Gen. Psychiatry 52, 850-856 (1998).
6. Kessler RC, Akiskal HS, Ames M et al.: Prevalence and effects of mood disorders on work performance in a nationally representative sample of U.S. workers. Am. J. Psychiatry 163(9), 561-568 (2006).
7. Cassano P, Fava M: Depression and public health: an overview. J. Psychosom. Res. 53(4), 849-857 (2002).
8. Lecrubier Y: Widespread underrecognition and undertreatment of anxiety and mood disorders: results from 3 European studies. J. Clin. Psychiatry 68(Suppl. 2), 36-41 (2007).
9. Mueller TI, Leon AC: Recovery, chronicity, and levels of psychopathology in major depression. Psychiatr. Clin. North Am. 9, 85-102 (1996).
10. Judd LL, Akiskal HS, Maser JD et al.: A prospective 12-year study of subsyndromal and syndromal depressive symptoms in unipolar major depressive disorders. Arch. Gen. Psychiatry 55, 694-700 (1998).
11. Thase ME, Howland RH: Refractory depression: relevance of psychosocial factors and therapies. Psychiatr. Ann. 24, 232-240 (1994).
12. Tranter R, O'Donovan C, Chandarana P et al.: Prevalence and outcome of partial remission in depression. J. Psychiatry Neurosci. 27(4), 241-247 (2002).
13. Rush AJ, Kraemer HC, Sackeim HA et al.: Report by the ACNP Task Force on response and remission in major depressive disorder. Neuropsychopharmacology 31(9), 1841-1853 (2006).
14. Fava M, Rush AJ, Trivedi MH et al.: Background and rationale for the sequenced treatment alternatives to relieve depression (STAR*D) study. Psychiatr. Clin. North Am. 26(2), 457-494 (2003).
15. McIntyre RS, O'Donovan C: The human cost of not achieving full remission in depression. Can. J. Psychiatry 49(3 Suppl. 1), S10-S16 (2004).
16. Hirschfeld RM, Keller MB, Panico S et al.: The National Depressive and Manic-Depressive Association consensus statement on the undertreatment of depression. JAMA 277(4), 333-340 (1997).
17. Wang PS, Simon G, Kessler RC: The economic burden of depression and the cost-effectiveness of treatment. Int. J. Methods Psychiatr Res. 12(1), 22-33 (2003).
18. Rush AJ: STAR*D: what have we learned? Am. J. Psychiatry 164(2), 201-204 (2007).
19. Rush AJ, Trivedi MH, Wisniewski SR et al.: Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am. J. Psychiatry 163, 1905-1917 (2006).
20. Montgomery SA: Why do we need new and better antidepressants? Int. Clin. Psychopharmacol. 21(Suppl. 1), S1-S10 (2006).
21. Stahl SM, Grady MM, Moret C et al.: SNRIs: their pharmacology, clinical efficacy, and tolerability in comparison with other classes of antidepressants. CNS Spectr. 10(9), 732-47 (2005).
22. Manji HK, Drevets WC, Charney DS: The cellular neurobiology of depression. Nat. Med. 7(5), 541-547 (2001).
23. Tran PV, Bymaster FP, McNamara RK et al.: Dual monoamine modulation for improved treatment of major depressive disorder. J. Clin. Psychopharmacol. 23, 78-86 (2003).
24. Vaishnavi SN, Nemeroff CB, Plott SJ et al.: Milnacipran: a comparative analysis of human monoamine uptake and transporter binding affinity. Biol. Psychiatry 55(3), 320-322 (2004).
25. Thase ME: Evaluating antidepressant therapies: remission as the optimal outcome. J. Clin. Psychiatry 64(Suppl. 13), 18-25 (2003).
26. Thase ME, Entsuah AR, Rudolph RL: Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors. Br. J. Psychiatry 178, 234-241 (2001).
27. Smith D, Dempster C, Glanville J et al.: Efficacy and tolerability of venlafaxine compared with selective serotonin reuptake inhibitors and other antidepressants: a meta-analysis. Br. J. Psychiatry 180, 396-404 (2002).
28. Fava M: The role of the serotonergic and noradrenergic neurotransmitter systems in the treatment of psychological and physical symptoms of depression. J. Clin. Psychiatry 64(Suppl. 13), 26-29 (2003).
29. Greden JF: Physical symptoms of depression: unmet needs. J. Clin. Psychiatry 64 (Suppl. 7), 5-11 (2003).
30. Rowbotham MC, Goli V, Kunz NR et al.: Venlafaxine extended release in the treatment of painful diabetic neuropathy: a double-blind, placebo-controlled study. Pain 110(3), 697-706 (2004).
31. Vitton O, Gendreau M, Gendreau J et al.: A double-blind placebo-controlled trial of milnacipran in the treatment of fibromyalgia. Hum. Psychopharmacol. 19(Suppl. 1), S27-S35 (2004).
32. Arnold LM, Lu Y, Crofford LJ et al.: A double-blind multicenter trial comparing duloxetine with placebo in the treatment of fibromyalgia patients with or without major depressive disorder. Arthritis Rheum. 50, 2974-2984 (2004).
33. Brennan SK, Mallinckdrot CH, Brown EB et al.: Duloxetine 60 mg once-daily in the treatment of painful physical symptoms in patients with major depressive disorder. J. Psychiatr. Res. 39(1), 43-53 (2005).
34. Bradley RH, Barkin RL, Jerome J et al.: Efficacy of venlafaxine for the long term treatment of chronic pain with associated major depressive disorder. Am. J. Ther. 10(5), 318-323 (2003).
35. Ozyalcin SN, Talu GK, Kiziltan E et al.: The efficacy and safety of venlafaxine in the prophylaxis of migraine. Headache 45(2), 144-152 (2005).
36. Evans ML, Pritts E, Vittinghoff E, McClish K et al.: Management of postmenopausal hot flashes with venlafaxine hydrochloride: a randomized, controlled trial. Obstet. Gynecol. 105, 161-166 (2005).
37. Nelson HD, Vesco KK, Haney E et al.: Nonhormonal therapies for menopausal hot flashes: systematic review and meta-analysis. JAMA 295(17), 2057-2071 (2006).
38. Harvey AT, Rudolph RL, Preskorn SH: Evidence of the dual mechanisms of action of venlafaxine. Arch. Gen. Psychiatry 57(5), 503-509 (2000).
39. Frazer A: Serotonergic and noradrenergic reuptake inhibitors: prediction of clinical effects from in vitro potencies. J. Clin. Psychiatry 62(Suppl. 12), 16-23 (2001).
40. Kelsey JE: Dose-response relationship with venlafaxine. J. Clin. Psychopharmacol. 16(3 Suppl. 2), S21-S28 (1996).
41. Dodd S, Berk M: Higher dose venlafaxine may improve response compared with standard doses in people with major depressive disorder and intolerance or non-responsiveness to SSRIs. Evid. Based Ment. Health. 10(1), 17 (2007).
42. Schweizer E, Thielen RJ, Frazer A:Venlafaxine: a novel antidepressant compound. Expert Opin. Investig. Drugs. 6(1), 65-78 (1997).
43. Deecher DC, Beyer CE, Johnston G et al.: Desvenlafaxine succinate: A new serotonin and norepinephrine reuptake inhibitor. J. Pharmacol. Exp. Ther. 318(2), 657-665 (2006).
44. Andree TH, Rosenzweig-Lipson S, Lin Q et al.: Preclinical evidence for antidepressant and anxiolytic efficacy of the new dual serotonin and norepinephrine reuptake inhibitor desvenlafaxine succinate (DVS). Presented at: Annual meeting of the Collegium Internationale Neuro-Psychopharmacologicum. Chicago, IL, USA, 9-13 July 2006.
45. Parker V, LS Richards, AI Nichols et al.: The absolute bioavailability of sustained-release formulation of desvenlafaxine succinate extended release in healthy subjects. Presented at: American Society for Clinical Pharmacology and Therapeutics Annual Meeting. Orlando, FL, USA, 2 March 2005.
46. Parks V, Patat A, Behrle J et al.: Safety, pharmacokinetics (PK) and pharmacodynamics (PD) of ascending single oral doses of sustained-release desvenlafaxine succinate (DVS-SR) in healthy subjects. Presented at: American Society for Clinical Pharmacology and Therapeutics Annual Meeting. Orlando, FL, USA, 2 March 2005.
47. Shilling AD, Yung-Sciame R, Leung L: Comparison of inhibitory effects of desvenlafaxine succinate, venlafaxine, duloxetine, paroxetine, sertraline, and bupropion in human cytochrome P450 activities. Presented at: International Society for the Study of Xenobiotics Meeting. Maui, Hawaii, USA, 23-27 October 2005.
48. Preskorn SH, Borges-Gonzalez S, Flockhart D: Clinically relevant pharmacology of neuropsychiatric drugs approved over the last three years: Part II. J. Psychiatr. Pract. 12(5), 312-316 (2006).
49. Baird-Bellaire? S, Patat A, Faunoux N et al.: Effects of chronic hepatic impairment on the pharmacokinetics and safety of desvenlafaxine succinate extended release. Presented at: American Society for Clinical Pharmacology and Therapeutics Annual Meeting. Baltimore, MA, USA, 7-11 March 2006.
50. Septein-Velez L, Pitrosky B, Padmanabhan S et al.: A randomized, double-blind, placebo-controlled trial of desvenlafaxine succinate in the treatment of major depressive disorder. Presented at: American Psychiatric Association Annual Meeting. Toronto, Canada, 20-25 May 2006.
51. DeMartinis NA, Yeung PP, Entsuah R et al.: A double-blind placebo-controlled study of the efficacy and safety of desvenlafaxine succinate in the treatment of major depressive disorder. J. Clin. Psychiatry 68, 677-688 (2007).
52. DeLoach LJ, Higgins MS, Caplan AB et al.: The visual analog scale in the immediate postoperative period: intrasubject variability and correlation with a numeric scale. Anesth. Analg. 86, 102-106 (1998).
53. Sheehan DV, Harnett-Sheehan K, Raj BA: The measurement of disability. Int. Clin. Psychopharmacol. 11(Suppl. 3), 89-95 (1996).
54. Bonsignore M, Barkow K, Jessen F et al.: Validity of the five-item WHO well-being index (WHO-5) in an elderly population. Eur. Arch. Psychiatry Clin. Neurosci. 251(Suppl. 2), 27-31 (2001).
55. Cunningham LA: Once-daily venlafaxine extended release (XR) and venlafaxine immediate release (IR) in outpatients with major depression. Venlafaxine XR 208 Study Group. Ann. Clin. Psychiatry. 9(3), 157-164 (1997).
56. Nieuwstraten C, Labiris NR, Holbrook A: Systematic overview of drug interactions with antidepressant medications. Can. J. Psychiatry 51(5), 300-316 (2006).
57. Brisard C, Zitek BE, Ninan PT et al.: Treating the painful physical symptoms of depression with desvenlafaxine succinate versus placebo in depressed outpatients. Presented at: American Psychiatric Association Annual Meeting. San Diego, CA, USA, 19-24 May 2007.